Skip to main navigation Skip to search Skip to main content

Tumor-associated antigen peptides as anti-metastatic vaccines

  • Lea Eisenbach*
  • , Ofer Mandelboim
  • , Erez Bar-Haim
  • , Lior Carmon
  • , Hernan Copcow
  • , Khaled El-Shami
  • , Adrian Paz
  • , Dan Popovic
  • , Ezra Vadai
  • , Esther Tzehoval
  • , Michael Feldman
  • , Mati Fridkin
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Cytotoxic T-lymphocytes (CTLs) kill abnormal cells. CTLs recognize major histocompatibility complex class I molecules in complex with peptides derived from relevant antigens. The identification of tumor associated antigen peptides enabled the design of anti-tumor and anti-metastatic vaccines in a murine lung carcinoma.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
JournalInternational Journal of Peptide Research and Therapeutics
Volume5
Issue number5-6
DOIs
StatePublished - 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Immunotherapy
  • MHC class I
  • Tumor metastases

Fingerprint

Dive into the research topics of 'Tumor-associated antigen peptides as anti-metastatic vaccines'. Together they form a unique fingerprint.

Cite this